Abstract:Background Mitochondrial maladaptation is a key event in the transition from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to Steatohepatitis (MASH) up to fibrosis/cirrhosis. However, it remains to be defined how mitochondrial alterations evolve as the disease progresses. Aims We exploited a mice model fed high fat-high fructose diet (Amylin liver NASH (AMLN) diet) that resemble human MASLD to investigate the role of mitochondrial dysfunction in boosting severe disease. Method C57Bl/6 male mice were fed AMLN or standard diet for 14-22-28 weeks (Taconic-Biosciences), to feature simple steatosis, MASH, and fibrosis, respectively. Mitochondrial morphology and activity were assessed by TEM and Seahorse assays, respectively whereas mitobiogenesis and OXPHOS complexes by Western Blot. Results Mice fed AMLN diet recapitulated the human MASLD spectrum encompassing hepatic fat accumulation with a mixed micro/macro pattern, inflammation, and collagen deposition. TEM showed progressive morphologic dysfunction of mitochondria which appeared normo-shaped with rare misshapen ones in AMLN-steatosis and completely swollen in AMLN-MASH. In the fibrosis group we observed aberrant organelles with disorganized cristae and matrix loss. Mitochondrial derangement was paralleled by progressive fragmentation of endoplasmic reticulum, apoptotic nuclei and autophagic bodies. The mitophagy pathway was reduced in AMLN model and particularly in AMLN-fibrosis thus explaining the accumulation of damaged mitochondria. Furthermore, the citrate synthase and mitochondrial complexes activities alongside OXPHOS protein levels and ATP production were lowered across the disease, especially in the presence of MASH-fibrosis. The failed activity was paralleled by oxidative stress, lactate production and release of cell-free circulating mitochondrial-DNA, which reflects hepatic mitochondrial impairment. Consistently, the Seahorse assay showed a progressive reduction of oxygen consumption rate in primary hepatocytes isolated from mice fed AMLN diet. Conclusion By exploiting the AMLN mice model, we demonstrated that alterations in mitochondrial morphology, lifecycle and activity feature all disease stages, thus fostering the switching to MASH and fibrosis.

When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models

Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis

Modelling human liver disease: from steatotic liver disease to MASH-HCC

A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis

Positive Selection of Somatically Mutated Clones Identifies Adaptive Pathways in Metabolic Liver Disease

A New Non-Obese Steatohepatitis Mouse Model with Cardiac Dysfunction Induced by Addition of Ethanol to a High-Fat/High-Cholesterol Diet

A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma

Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis

Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model

Spatial transcriptomics reveals the transcriptomic signatures in a mouse model of pediatric metabolic dysfunction-associated steatohepatitis

Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis

Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis

Longitudinal Analysis of Mitochondrial Function in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis Mouse Model

Hepatic‐specific Pgc‐1α ablation drives fibrosis in a MASH model

Modeling Metabolic-Associated Steatohepatitis with Human Pluripotent Stem Cell-Derived Liver Organoids

Mitochondrial topoisomerase I (Top1MT) prevents the onset of metabolic dysfunction-associated steatohepatitis (MASH) in mice

Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids

Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH

Novel Choline-Deficient and 0.1%-Methionine-Added High-Fat diet Induces Burned-Out Metabolic-Dysfunction-Associated Steatohepatitis with Inflammation by Rapid Immune Cell Infiltration on Male Mice

A novel mouse model of lipotoxic cardiomyopathy

Diabetes as a risk factor for MASH progression